Synthetic HLA-independent T cell receptors for cancer immunotherapy.

CAR T cells are remarkably effective in hematologic malignancies, but tumor cells expressing low antigen levels can escape elimination. In Nature Medicine, Mansilla-Soto et al. design new chimeric receptors that link the variable regions of antibodies directly to T cell receptor chains and recognize tumor cells with improved antigen sensitivity.
Competing Interests: Declaration of interests S.R.R. is a founder of Juno Therapeutics, now Juno/Bristol Myers Squibb, and a founder of and advisor to Lyell Immunopharma. S.R.R. has patents related to the field of chimeric antigen receptor-modified T cells and their use in immunotherapy.
(Copyright © 2022 Elsevier Inc. All rights reserved.)